Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study

Emeline Colomba, Gwénaël Le Teuff, Tim Eisen, Grant D Stewart, Kate Fife, James Larkin, Andrea Biondo, Lisa Pickering, Anandagopal Srinivasan, Helen Boyle, Lisa Derosa, Cora N Sternberg, Federica Recine, Christy Ralph, Carolina Saldana, Philippe Barthélémy, Jean Christophe Bernhard, Howard Gurney, Gregory Verhoest, Elodie VauleonPierre Bigot, Julien Berger, Christian Pfister, Gwenaelle Gravis, Jean-Michel Rodier, Stéphane Culine, Armelle Caty, Frederic Rolland, Franck Priou, Bernard Escudier, Laurence Albiges

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.

METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.

RESULTS: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).

CONCLUSION: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.

Original languageEnglish
Pages (from-to)55-62
Number of pages8
JournalEuropean Journal of Cancer
Volume80
DOIs
Publication statusPublished - Jul 2017

Fingerprint

Sirolimus
Renal Cell Carcinoma
Treatment Failure
Kidney
Confidence Intervals
Survival
Therapeutics
Vascular Endothelial Growth Factor A
Databases
Prospective Studies
Neoplasm Metastasis

Keywords

  • Adult
  • Aged
  • Angiogenesis Inhibitors
  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Enzyme Inhibitors
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Kidney Neoplasms
  • Male
  • Middle Aged
  • Molecular Targeted Therapy
  • Retrospective Studies
  • Survival Analysis
  • TOR Serine-Threonine Kinases
  • Time Factors
  • Treatment Failure
  • Journal Article
  • Multicenter Study

Cite this

Metastatic chromophobe renal cell carcinoma treated with targeted therapies : A Renal Cross Channel Group study. / Colomba, Emeline; Le Teuff, Gwénaël; Eisen, Tim; Stewart, Grant D; Fife, Kate; Larkin, James; Biondo, Andrea; Pickering, Lisa; Srinivasan, Anandagopal; Boyle, Helen; Derosa, Lisa; Sternberg, Cora N; Recine, Federica; Ralph, Christy; Saldana, Carolina; Barthélémy, Philippe; Bernhard, Jean Christophe; Gurney, Howard; Verhoest, Gregory; Vauleon, Elodie; Bigot, Pierre; Berger, Julien; Pfister, Christian; Gravis, Gwenaelle; Rodier, Jean-Michel; Culine, Stéphane; Caty, Armelle; Rolland, Frederic; Priou, Franck; Escudier, Bernard; Albiges, Laurence.

In: European Journal of Cancer, Vol. 80, 07.2017, p. 55-62.

Research output: Contribution to journalArticle

Colomba, E, Le Teuff, G, Eisen, T, Stewart, GD, Fife, K, Larkin, J, Biondo, A, Pickering, L, Srinivasan, A, Boyle, H, Derosa, L, Sternberg, CN, Recine, F, Ralph, C, Saldana, C, Barthélémy, P, Bernhard, JC, Gurney, H, Verhoest, G, Vauleon, E, Bigot, P, Berger, J, Pfister, C, Gravis, G, Rodier, J-M, Culine, S, Caty, A, Rolland, F, Priou, F, Escudier, B & Albiges, L 2017, 'Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study', European Journal of Cancer, vol. 80, pp. 55-62. https://doi.org/10.1016/j.ejca.2017.03.011
Colomba, Emeline ; Le Teuff, Gwénaël ; Eisen, Tim ; Stewart, Grant D ; Fife, Kate ; Larkin, James ; Biondo, Andrea ; Pickering, Lisa ; Srinivasan, Anandagopal ; Boyle, Helen ; Derosa, Lisa ; Sternberg, Cora N ; Recine, Federica ; Ralph, Christy ; Saldana, Carolina ; Barthélémy, Philippe ; Bernhard, Jean Christophe ; Gurney, Howard ; Verhoest, Gregory ; Vauleon, Elodie ; Bigot, Pierre ; Berger, Julien ; Pfister, Christian ; Gravis, Gwenaelle ; Rodier, Jean-Michel ; Culine, Stéphane ; Caty, Armelle ; Rolland, Frederic ; Priou, Franck ; Escudier, Bernard ; Albiges, Laurence. / Metastatic chromophobe renal cell carcinoma treated with targeted therapies : A Renal Cross Channel Group study. In: European Journal of Cancer. 2017 ; Vol. 80. pp. 55-62.
@article{2038b543e1194e1cbf891d030d2b7034,
title = "Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study",
abstract = "BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.RESULTS: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95{\%} confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82{\%}) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95{\%} CI: 5.2-10.9) and 22.9 months (95{\%} CI: 17.8-49.2) versus 1.9 months (95{\%} CI: 1.0-6.0) and 3.2 months (95{\%} CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).CONCLUSION: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.",
keywords = "Adult, Aged, Angiogenesis Inhibitors, Antineoplastic Agents, Carcinoma, Renal Cell, Enzyme Inhibitors, Female, Humans, Kaplan-Meier Estimate, Kidney Neoplasms, Male, Middle Aged, Molecular Targeted Therapy, Retrospective Studies, Survival Analysis, TOR Serine-Threonine Kinases, Time Factors, Treatment Failure, Journal Article, Multicenter Study",
author = "Emeline Colomba and {Le Teuff}, Gw{\'e}na{\"e}l and Tim Eisen and Stewart, {Grant D} and Kate Fife and James Larkin and Andrea Biondo and Lisa Pickering and Anandagopal Srinivasan and Helen Boyle and Lisa Derosa and Sternberg, {Cora N} and Federica Recine and Christy Ralph and Carolina Saldana and Philippe Barth{\'e}l{\'e}my and Bernhard, {Jean Christophe} and Howard Gurney and Gregory Verhoest and Elodie Vauleon and Pierre Bigot and Julien Berger and Christian Pfister and Gwenaelle Gravis and Jean-Michel Rodier and St{\'e}phane Culine and Armelle Caty and Frederic Rolland and Franck Priou and Bernard Escudier and Laurence Albiges",
note = "Copyright {\circledC} 2017. Published by Elsevier Ltd.",
year = "2017",
month = "7",
doi = "10.1016/j.ejca.2017.03.011",
language = "English",
volume = "80",
pages = "55--62",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",

}

TY - JOUR

T1 - Metastatic chromophobe renal cell carcinoma treated with targeted therapies

T2 - A Renal Cross Channel Group study

AU - Colomba, Emeline

AU - Le Teuff, Gwénaël

AU - Eisen, Tim

AU - Stewart, Grant D

AU - Fife, Kate

AU - Larkin, James

AU - Biondo, Andrea

AU - Pickering, Lisa

AU - Srinivasan, Anandagopal

AU - Boyle, Helen

AU - Derosa, Lisa

AU - Sternberg, Cora N

AU - Recine, Federica

AU - Ralph, Christy

AU - Saldana, Carolina

AU - Barthélémy, Philippe

AU - Bernhard, Jean Christophe

AU - Gurney, Howard

AU - Verhoest, Gregory

AU - Vauleon, Elodie

AU - Bigot, Pierre

AU - Berger, Julien

AU - Pfister, Christian

AU - Gravis, Gwenaelle

AU - Rodier, Jean-Michel

AU - Culine, Stéphane

AU - Caty, Armelle

AU - Rolland, Frederic

AU - Priou, Franck

AU - Escudier, Bernard

AU - Albiges, Laurence

N1 - Copyright © 2017. Published by Elsevier Ltd.

PY - 2017/7

Y1 - 2017/7

N2 - BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.RESULTS: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).CONCLUSION: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.

AB - BACKGROUND: Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian Target of Rapamycin (mTOR) inhibitors are used, extrapolating the data from use of these agents in clear cell RCC.METHODS: We performed a retrospective data analysis within the Renal Cross Channel Group to determine metastatic chromophobe RCC (mChRCC) outcomes in the TT era. The end-points were overall response, overall survival (OS) and time to treatment failure (TTF). The two latter were estimated using the Kaplan-Meier method.RESULTS: 91 mChRCC patients from 26 centres were included. Median follow-up from the date of first metastasis was 6.1 years (range: 0-13.9). Median OS was 37.9 months (95% confidence interval [CI]: 21.4-46.8) from the diagnosis of metastatic disease. Among the 61 patients who received TT, 50 (82%) were treated with anti-angiogenic (AA) and 11 with mTOR inhibitors. Median TTF and OS in patients receiving a first line of AA was 8.7 months (95% CI: 5.2-10.9) and 22.9 months (95% CI: 17.8-49.2) versus 1.9 months (95% CI: 1.0-6.0) and 3.2 months (95% CI: 2.3-not evaluable) with mTOR inhibitors, respectively. A stratified log-rank test was used to compare AA and mTOR inhibitors TT, while controlling the effect of the International Metastatic RCC Database Consortium risk group and no significant difference between AA and mTOR inhibitors was observed for TTF (p = 0.26) or for OS (p = 0.55).CONCLUSION: We report the largest retrospective cohort of patients with mChRCC treated with TT and no significant difference between AA and mTOR inhibitors was observed for TTF and OS.

KW - Adult

KW - Aged

KW - Angiogenesis Inhibitors

KW - Antineoplastic Agents

KW - Carcinoma, Renal Cell

KW - Enzyme Inhibitors

KW - Female

KW - Humans

KW - Kaplan-Meier Estimate

KW - Kidney Neoplasms

KW - Male

KW - Middle Aged

KW - Molecular Targeted Therapy

KW - Retrospective Studies

KW - Survival Analysis

KW - TOR Serine-Threonine Kinases

KW - Time Factors

KW - Treatment Failure

KW - Journal Article

KW - Multicenter Study

U2 - 10.1016/j.ejca.2017.03.011

DO - 10.1016/j.ejca.2017.03.011

M3 - Article

C2 - 28549248

VL - 80

SP - 55

EP - 62

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -